Targeting signal transduction pathways in colorectal cancer - More than skin deep

Journal of Clinical Oncology

Volumn 23, Issue 23, 2005, Pages 5374-5385

  Cohen, Steven J ^a   Cohen, Roger B ^a   Meropol, Neal J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; ATN 161; CETUXIMAB; CGP 69846A; CP 751 871; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMATINIB; IMC A12; IRINOTECAN; ISIS 2503; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN; MAPATUMUMAB; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LM 609; MONOCLONAL ANTIBODY TRM 1; PANITUMUMAB; PLATELET DERIVED GROWTH FACTOR; RAS PROTEIN; SOMATOMEDIN RECEPTOR; SORAFENIB; SUNITINIB; TIPIFARNIB; TRASTUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; WX UK1; ENZYME INHIBITOR; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; GASTROINTESTINAL TUMOR; HUMAN; METASTASIS; MONOTHERAPY; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SKIN TOXICITY; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 23944469938     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.194     Document Type: Review

References (154)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Andre T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004
3. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
4. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
6. O'Connell MJ, Mailliard JA, Kahn MJ, et al: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15:246-250, 1997
7. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
8. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
9. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
10. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004
11. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
12. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970, 2001
13. Wu X, Fan Z, Masui H, et al: Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95:1897-1905, 1995
14. Prewett MC, Hooper AT, Bassi R, et al: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8:994-1003, 2002
15. Mayer A, Takimoto M, Fritz E, et al: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71:2454-2460, 1993
16. Resnick MB, Routhier J, Konkin T, et al: Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: A tissue microarray study. Clin Cancer Res 10:3069-3075, 2004
17. Damjanov N, Meropol NJ: Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: A promise fulfilled? Oncology (Huntingt) 18:479-88, 493, 497, 2004
18. Oza A, Townsley C, Siu L, et al: Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 22:196, 2003 (abstr 785), 2003
19. Rothenberg M, Lafleur B, Washington M, et al: Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer (MCRC) treated with gefitinib (ZD1839): An Eastern Cooperative Oncology Group study. Proc Am Soc Clin Oncol 22:195s, 2004 (abstr 3000; suppl)
20. Saltz LRM, Rubin M, Hochster H, et al: Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20:3a, 2001 (abstr 7)
21. Hecht J, Patnaik A, Malik I, et al: ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. Proc Am Soc Clin Oncol 22:247s, 2004 (abstr 3511; suppl)
22. Vanhoefer U, Tewes M, Rojo F, et al: Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22:175-184, 2004
23. Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005
24. Lenz H, Mayer R, Gold P, et al: Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 22:247s, 2004 (abstr 3510; suppl)
25. Saltz L, Kies M, Abbruzzese J, et al: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22:204, 2003 (abstr 817)
26. Salazar R, Tabernero J, Rojo F, et al: Dose-dependent inhibition of the EGFR and signaling pathways with the anti-EGFR monoclonal antibody (MAb) EMD 72000 administered every three weeks (q3w): A phase I pharmacokmetic/ pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). Proc Am Soc Clin Oncol 22:127s, 2004 (abstr 2002; suppl)
27. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004
28. Nagahara H, Mimori K, Ohta M, et al: Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 11:1368-1371, 2005
29. Barber TD, Vogelstein B, Kinzler KW, et al: Somatic mutations of EGFR in colorectal cancers and gliobiastomas. N Engl J Med 351:2883, 2004
30. Meropol NJ: Epidermal growth factor receptor inhibitors in colorectal cancer: It's time to get back on target. J Clin Oncol 23:1791-1793, 2005
31. D'Ercole AJ, Stiles AD, Underwood LE: Tissue concentrations of somatomedin C: Further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A 81:935-939, 1984
32. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472-1489, 2000
33. Petley T, Graft K, Jiang W, et al: Variation among cell types in the signaling pathways by which IGF-I stimulates specific cellular responses. Horm Metab Res 31:70-76, 1999
34. Chakravarti A, Loeffler JS, Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200-207, 2002
35. Lambert S, Vivario J, Boniver J, et al: Abnormal expression and structural modification of the insulin-like growth-factor-II gene in human colorectal tumors. Int J Cancer 46:405-410, 1990
36. Weber MM, Fottner C, Liu SB, et al: Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086-2095, 2002
37. Remacle-Bonnet MM, Garrouste FL, Heller S, et al: Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 60:2007-2017, 2000
38. Reinmuth N, Liu W, Fan F, et al: Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 8:3259-3269, 2002
39. Bauer TWMM, McCarty MF, Wey J, et al: Combination therapy with insulin-like growth factor-I receptor (IGF-IR) antibody plus oxaliplatin decreases hepatic growth of human colon cancer. ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 22-24, 2004 (abstr 279)
40. Lu D, Zhang H, Koo H, et al: A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280:19665-19672, 2005
41. ImClone Systems Incorporated, Research. http://www.imclone.com/content. php? pg=research.htm
42. Cohen BD, Baker DA, Soderstrom C, et al: Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073, 2005
43. Heldin CH, Eriksson U, Ostman A: New members of the platelet-derived growth factor family of mitogens. Arch Biochem Biophys 398:284-290, 2002
44. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316, 1999
45. Pietras K, Sjoblom T, Rubin K, et al: PDGF receptors as cancer drug targets. Cancer Cell 3:439-443, 2003
46. Bergers G, Song S, Meyer-Morse N, et al: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295, 2003
47. Takahashi Y, Bucana CD, Liu W, et al: Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells. J Natl Cancer Inst 88:1146-1151, 1996
48. Hsu S, Huang F, Friedman E: Platelet-derived growth factor-B increases colon cancer cell growth in vivo by a paracrine effect. J Cell Physiol 165:239-245, 1995
49. Pietras K, Ostman A, Sjoquist M, et al: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929-2934, 2001
50. Attoub S, Rivat C, Rodrigues S, et al: The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62:4879-4883, 2002
51. Zhou L. An N, Haydon RC, et al: Tyrosine kinase inhibitor STI-571/Gleevec down-regulates the beta-catenin signaling activity. Cancer Lett 193:161-170, 2003
52. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor-receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
53. Gross A, McDonnell JM, Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899-1911, 1999
54. Morris MJ, Tong WP, Cordon-Cardo C, et al: Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 8:679-683, 2002
55. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682, 1995
56. MacFarlane M, Ahmad M, Srinivasula SM, et al: Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 272:25417-25420, 1997
57. Pan G, O'Rourke K, Chinnaiyan AM, et al: The receptor for the cytotoxic ligand TRAIL. Science 276:111-113, 1997
58. Li H, Zhu H, Xu CJ, et al: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501, 1998
59. Strater J, Hinz LJ, Walczak H, et al: Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 8:3734-3740, 2002
60. Naka T, Sugamura K, Hylander BL, et al: Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62:5800-5806, 2002
61. Gliniak B, Le T: Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59:6153-6158, 1999
62. Salcedo T, Alderson R, Basu S, et al: TRM-1, a human TRAIL-R1 agonistic monoclonal antibody, displays in vitro and in vivo anti-tumor activity. Proc Am Assoc Cancer Res 43:71, 2002 (abstr 4240)
63. Pukac L, Kanakaraj P, Humphreys R, et al: HGS-ETR1, a fully human TRAIL receptor 1 monoclonal antibody, induces cell death in multiple tumor types in vitro and in vivo. Br J Cancer 92:1430-1441, 2005
64. Le L, Hirte H, Hotte S, et al: Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 22:171 s, 2004 (abstr 2533; suppl)
65. Tolcher A, Mita M, Patnaik A, et al: A phase I and pharmacokinetic study of HGS-ETR1(TRM-1), a human monoclonal agonist-antibody to TRAIL R1, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 22:210s, 2004 (abstr 3060; suppl)
66. de Bono J, Attard G, Pacey S, et al: A Phase 1 safety and pharmacokinetic (PK) Study of an agonistic, fully human monoclonal antibody, HGS-ETR2, to the TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) in patients with advanced cancer. EJC Supplements 2:61, Geneva Switzerland, September 28-October 1, 2004 (abstr 197)
67. Kelley RF, Totpal K, Lindstrom SH, et al: Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280:2205-2212, 2005
68. Murillo CA, Rychahou PG, Evers BM: Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers. Surgery 136:143-149, 2004
69. Reinmuth N, Liu W, Ahmad SA, et al: Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 63:2079-2087, 2003
70. Playford MP, Schaller MD: The interplay between Src and integrins in normal and tumor biology. Oncogene 23:7928-7946, 2004
71. Stoeltzing O, Liu W, Reinmuth N, et al: Inhibition of integrin alpha5beta1 function with a small peptide (ATM-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer 104:496-503, 2003
72. Posey JA, Khazaeli MB, DelGrosso A, et al: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. Cancer Biother Radiopharm 16:125-132, 2001
73. Protein Design Labs, Anti-alpha5beta1 integrin. http://www.pdl.com/index. cfm?navId= 102
74. Eskens FA, Dumez H, Hoekstra R, et al: Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917-926, 2003
75. Harbeck N, Kates RE, Schmitt M, et al: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Cancer 5:348-352, 2004
76. Chapman HA, Wei Y, Simon DI, et al: Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 82:291-297, 1999
77. Ahmed N, Oliva K, Wang Y, et al: Down-regulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR-beta1 integrin complex in colon cancer cells. Br J Cancer 89:374-384, 2003
78. Liu D, Aguirre Ghiso J, Estrada Y, et al: EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1:445-457, 2002
79. de Bruin PA, Griffioen G, Verspaget HW, et al: Plasminogen activators and tumor development in the human colon: Activity levels in normal mucosa, adenomatous polyps, and adenocarcinomas. Cancer Res 47:4654-4657, 1987
80. Fujii T, Obara T, Tanno S, et al: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology 46:2299-2308, 1999
81. Wang Y, Liang X, Wu S, et al: Inhibition of colon cancer metastasis by a 3′-end antisense urokinase receptor mRNA in a nude mouse model. Int J Cancer 92:257-262, 2001
82. Servomaa K, Kiuru A, Kosma VM, et al: p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol 53:24-30, 2000
83. Bos JL: ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689, 1989
84. Rao S, Cunningham D, de Gramont A, et al: Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol 22:3950-3957, 2004
85. Sharma S, Kemeny N, Kelsen DP, et al: A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 13:1067-1071, 2002
86. Cunningham CC, Holmlund JT, Geary RS, et al: A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma. Cancer 92:1265-1271, 2001
87. Saleh M, Posey J, Pleasant L, et al: A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma. Proc Am Soc Clin Oncol 19:318a, 2000 (abstr 1258)
88. Lobell RB, Liu D, Buser CA, et al: Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl: protein transferase type-I. Mol Cancer Ther 1:747-758, 2002
89. Miller SC, Mitchison TJ: Synthesis and phenotypic screening of a Guanine-mimetic library. ChemBioChem 5:1010-1012, 2004
90. Whyte DB, Kirschmeier P, Hockenberry TN, et al: K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272:14459-14464, 1997
91. Cohen SJ, Ho L, Ranganathan S, et al: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 21:1301-1306, 2003
92. Wellbrock C, Karasarides M, Marais R: The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875-885, 2004
93. Nagasaka T, Sasamoto H, Notohara K, et al: Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 22:4584-4594, 2004
94. Cripps MC, Figueredo AT, Oza AM, et al: Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: A National Cancer Institute of Canada Clinical Trials Group study. Clin Cancer Res 8:2188-2192, 2002
95. Gokhale PC, Zhang C, Newsome JT, et al: Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome. Clin Cancer Res 8:3611-3621, 2002
96. Rudin CM, Marshall JL, Huang CH, et al: Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: A phase I study. Clin Cancer Res 10:7244-7251, 2004
97. Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64:7099-7109, 2004
98. Strumberg D, Richly H, Hilger RA, et al: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23:965-972, 2005
99. Ratain M, Flaherty K, Stadler W, et al: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT). Proc Am Soc Clin Oncol 22:382s, 2004 (abstr 4501; suppl)
100. Kupsch P, Passarge K, Richly H, et al: Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors. Proc Am Soc Clin Onco 22:209s, 2004 (abstr 3056; suppl)
101. Mross K, Steinbild S, Baas F, et al: Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharmacol Ther 41:618-619, 2003
102. Cobb MH, Goldsmith EJ: How MAP kmases are regulated. J Biol Chem 270:14843-14846, 1995
103. Sebolt-Leopold JS, Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937-947, 2004
104. Hoshino R, Chatani Y, Yamori T, et al: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813-822, 1999
105. Wang Z, Li Y, Liu ET, et al: Susceptibility to cell death induced by blockade of MARK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status. Biochem Biophys Res Commun 322:609-613, 2004
106. Sebolt-Leopold JS, Dudley DT, Herrera R, et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5:810-816, 1999
107. LoRusso P, Adjei A, Meyer M, et al: A phase 1 clinical and pharmacokinetic evaluation of the oral MEK inhibitor, CI-1040, administered for 21 consecutive days, repeated every 4 weeks in patients with advanced cancer. Proc Am Soc Clin Oncol 21: 81a, 2002 (abstr 321)
108. Rinehart J, Adjei AA, Lorusso PM, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462, 2004
109. Lee P, Wallace E, Yen T, et al: ARRY-142886, a potent and selective MEK inhibitor: III) Efficacy in murine xenograft models correlates with decreased ERK phosphorylation. Proc Am Assoc Cancer Res 45, 2004 (abstr 3890)
110. Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98:10983-10985, 2001
111. Raffioni S, Bradshaw RA. Activation of phosphatidylinositol 3-kinase by epidermal growth factor, basic fibroblast growth factor, and nerve growth factor in PC12 pheochromocytoma cells. Proc Natl Acad Sci U S A 89:9121-9125, 1992
112. Thompson JE, Thompson CB: Putting the rap on Akt. J Clin Oncol 22:4217-4226, 2004
113. Cross DA, Alessi DR, Cohen P, et al: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789, 1995
114. Muise-Helmericks RC, Grimes HL, Bellacosa A, et al: Cyclin D expression is controlled post-transcnptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273:29864-29872, 1998
115. Collado M, Medema RH, Garcia-Cao I, et al: Inhibition of the phosphoinositide 3-kinase pathway induces a senescence-like arrest mediated by p27Kip1. J Biol Chem 275:21960-21968, 2000
116. Sonenberg N, Gingras AC: The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr Opin Cell Biol 10:268-275, 1998
117. Fulton D, Gratton JP, McCabe TJ, et al: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399:597-601, 1999
118. Kim D, Kim S, Koh H, et al: Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 15:1953-1962, 2001
119. Kang SS, Kwon T, Kwon DY, et al: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 274:13085-13090, 1999
120. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501, 2002
121. Khaleghpour K, Li Y, Banville D, et al: Involvement of the PI 3-kinase signaling pathway in progression of colon adenocarcinoma. Carcinogenesis 25:241-248, 2004
122. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554, 2004
123. Meuillet EJ, Ihle N, Baker AF, et al: In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 14:513-527, 2004
124. Ihle NT, Williams R, Chow S, et al: Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol Cancer Ther 3:763-772, 2004
125. Van Ummersen L. Binger K, Volkman J, et al: A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10:7450-7456, 2004
126. Hidalgo M, Rowinsky EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19:6680-6686, 2000
127. Hara K, Yonezawa K, Kozlowski MT, et al Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272:26457-26463, 1997
128. Kumar V, Sabatini D, Pandey P, et al: Regulation of the rapamycin and FKBP-target 1/mammalian target of rapamycin and cap-dependent initiation of translation by the c-Abl protein-tyrosine kinase. J Biol Chem 275:10779-10787, 2000
129. Aoki M, Blazek E, Vogt PK: A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 98:136-141, 2001
130. Sehgal SN, Baker H, Vezina C: Rapamycin (AY-22,989), a new antifungal antibiotic: II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 28:727-732, 1975
131. DeGraffenried LA, Fulcher L, Friedrichs WE, et al: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann Oncol 15:1510-1516, 2004
132. Clackson T, Metcalf C, Rivera V, et al: Broad anti-tumor activity of ap23573, an mTOR inhibitor in clinical development. Proc Am Soc Clin Oncol 22:220, 2003 (abstr 882)
133. O'Reilly T, Vaxelaire J, Muller M, et al: In vivo activity of RAD001, an orally active rapamycin derivative, in experimental tumor models. Proc Am Assoc Cancer Res 43:71, 2002 (abstr 359)
134. O'Donnell A, Faivre S, Judson I, et al: A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc Am Soc Clin Oncol 22:200, 2003 (abstr 803)
135. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004
136. Punt CJ, Boni J, Bruntsch U, et al: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and ieucovorin in patients with advanced solid tumors. Ann Oncol 14:931-937, 2003
137. Peralba JM, DeGraffenried L, Friedrichs W, et al: Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887-2892, 2003
138. Cao X, Tay A, Guy GR, et al: Activation and association of Stat3 with Src in v-Src-transformed cell lines. Mol Cell Biol 16:1595-1603, 1996
139. Courter DL, Lomas L, Scatena M, et al: SRC kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear J Biol Chem 280:12145-12151, 2005
140. Brunton VG, Avizienyte E, Fincham VJ, et al: Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior. Cancer Res 65:1335-1342, 2005
141. Muthuswamy SK, Muller WJ: Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 11:271-279, 1995
142. Biscardi JS, Ishizawar RC, Silva CM, et al: Tyrosine kinase signalling in breast cancer, epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2:203-210, 2000
143. Aligayer H, Boyd DD, Heiss MM, et al: Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94:344-351, 2002
144. Sawyers CL, Shah NP, Kantarjian HM, et al: hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study. Blood (ASH Annual Meeting abstracts) 104: San Diego, CA, December 4-7, 2004
145. Gallagher N, Lockton A, Macpherson M, et al: A phase I multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, orally available, dual-specific Src-Abl kinase inhibitor. Proc Am Assoc Cancer Res 46, 2005 (abstr 3972)
146. Grafone T, Mancini M, Ottaviani E, et al: A novel 4-anilino-3- quinolinecarbonitrile dual Src and Abl kinase inhibitor (SKI-606) has in vitro activity on CML Ph + Blast cells resistant to imatinib. Proc Am Assoc Cancer Res 46, 2005 (abstr 5984)
147. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
148. Christine R, Sylvie R, Erik B, et al: Implication of STAT3 signaling in human colonic cancer cells during intestinal trefoil factor 3 (TFF3) and vascular endothelial growth factor-mediated cellular invasion and tumor growth. Cancer Res 65:195-202, 2005
149. Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4:927-936, 2004
150. Bischoff JR, Anderson L, Zhu Y, et al: A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17:3052-3065, 1998
151. Harrington EA, Bebbington D, Moore J, et al: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262-267, 2004
152. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147, 2004
153. Cohen S, Alpaugh R, Allard J, et al: Isolation and characterization of circulating tumor cells in patients with colorectal cancer. Proc Am Soc Clin Oncol 22:295, 2003 (abstr 1186)
154. Baselga J, Rischin D, Ranson M, et al: Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292-4302, 2002